Naslov
Antibodies in NIDDM serum binding to advanced glycation modified proteins

Autori
Turk, Zdenka ; Ljubić, Spomenka ; Benko, Bojan ; Granić, Mate

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the Aannual Meeting of the European Association for the Study of Diabetes ; u: Diabetologia 42 (1999) (S1) / Ferannini, E. - Heidelberg : Springer, 1999, A57-A57

Skup
Aannual Meeting of the European Association for the Study of Diabetes

Mjesto i datum
Bruxelles, Belgija, 28.09.1999. - 03.10.1999

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
diabetes; advanced glycation; autoantibodies

Sažetak
The evidence that advanced glycation endproducts (AGEs) have antigenic properties have led to a hypothesis that AGE as an antigen being continuously formed in a diabetic body may arouse an autoimmune response. The aim of this study was to investigate the AGE level and anti-AGE response in NIDDM patients (35 without microangiopathy and 15 with nephropathy and/or retinopathy), and in 20 nondiabetic controls. Competitive ELISA was developed to measure AGEs in serum, and inhibition assay was used to detect anti-AGE response. A purified immunoglobulin fraction from human plasma (4500 healthy donors) of normal subclass distribution was used as a standard. AGE- modified IgG was used as antigen to detect anti- IgG-AGE positive samples. The binding inhibition assay showed a significant difference between diabetic subjects and nondiabetic controls (36.2ą3.9% vs 26.4ą3.6%, p<0.0004) (meanąSE). There also was a significant difference in AGE levels between diabetic patients and control subjects (51.6ą4.2 vs 19.8ą1.7 AU/mg, p<0.001). The binding inhibition percentage differed between the diabetics with nephropathy and/or retinopathy (42.0ą7.2%), and those free from complications (33.5ą4.6%), but the difference was not statistically significant. Spearman correlation showed an inverse relationship between the binding inhibition percentage and parameters of nonenzymatic glycation, HbA1c (r= -0.4, p<0.002) and AGE level (r= -0.35, p<0.004). Anti-IgG-AGE positive individuals were detected in both NIDDM groups. These data indicate a stronger immune response to proteins modified by advanced glycation in diabetic subjects than in healthy age-matched controls. Long-term presence of both antigens and antigen-specific antibodies might be the cause of a series of undesired phenomena. There is a possibility that antiAGEab form immune complexes which are believed to have a role in atherogenesis. Therefore, additional studies are needed to establish the role and significance of autoantibodies against AGEs in atherogenic processes in diabetes.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA